For our friends in Japan, we kindly suggest the following sessions at this year's annual meeting in Boston, MA.
What are the areas of potential risks when undertaking global clinical trials in emerging markets?
GCPs in Emerging Countries
What are the GCP quality trends in US and emerging countries?
What are differences in legislation for risk management between the US, EU and Japan?
Pharmaceuticals and Medical Devices Agency (PMDA) Town Hall
PMDA Town Hall: Japanese regulation activities and initiatives
What is the current drug supply situation in US, EU and Japan?
What are latest developments in pharmacovigilance in the developing countries of Asia and Latin America?
What are similarities/differences in Biosimilar regulatory requirements in APAC and Latin America?
Sign up for DIA's Global SmartBrief eNews for the latest in drug development innovations worldwide.